TG Therapeutics: An Immunology Powerhouse | Latest News RSS feed

TG Therapeutics: An Immunology Powerhouse - Latest News

TG Therapeutics: An Immunology Powerhouse

Finances: Enough liquid assets to support the company until at least Q1 2019, with similar cash burns expected in the near future. Market potential by indication: $1.7 billion (relapsed/refractory CLL ... read more

Bristol-Myers Squibb to Acquire Celgene for $74B

Bristol-Myers Squibb (BMS) plans to acquire Celgene for approximately $74 billion, the companies said today, in a blockbuster deal designed to create a powerhouse in immunology and ... moves such as ... read more

Here's What Bristol-Myers Squibb Will Look Like After Acquiring Celgene

Once Bristol-Myers Squibb completes its planned acquisition of Celgene, it will be an oncology powerhouse. Bristol-Myers Squibb ... for Bristol-Myers Squibb to become a top-five player in immunology ... read more

Looking for another news?

Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology Antibodies

Checkpoint and TG Therapeutics ... Checkpoint Therapeutics, Inc., to develop a portfolio of fully human immuno-oncology targeted antibodies generated in the laboratory of Dr. Wayne Marasco, MD, PhD, a ... read more

Technavio Announces Top Ten Vendors in the Global Chronic Lymphocytic Leukemia Market from 2016 to 2020

Companies such as BioLineRx, Emergent BioSolutions, Infinity Pharmaceuticals, and TG Therapeutics are expected to enter ... and sells products across various therapy areas, including immunology, ... read more

2015, a Strategic Year for LFB

In 2015, the group posted encouraging operational income (€17 million), notably owing to its holding in the bio-tech company TG Therapeutics Inc. The positive ... and often rare diseases in the fields ... read more

Flare-responsive hydrogel developed to treat arthritis

"Although new therapeutics have been developed ... The newly created flare-responsive hydrogel is made from triglycerol monostearate (TG-18), a compound from the Food and Drug Administration's list of ... read more

3 Top Biotech Stocks to Buy in January

The deal will combine Bristol-Myers' and Celgene's core oncology and immunology segments ... This would include Celgene's multiple myeloma powerhouse Revlimid, which could soon become the top-selling ... read more

Investors Should Exercise Caution With REVO Biologics IPO

Dr. Echelard currently serves as a director of TG Therapeutics (NASDAQ: TGTX) and as a director of GTC Biotherapeutics UK Limited. Dr. Echelard received a Ph.D. in microbiology and immunology from the ... read more

Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology Antibodies

In connection with the license agreement with Dana-Farber, Checkpoint Therapeutics entered into a collaboration agreement with TG Therapeutics, Inc. TGTX, -1.49% to develop and commercialize the ... read more

FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us